


WWL123 analogue-1

Cat. No.:	HY-132246		
CAS No.:	1338575-41-9		
Molecular Formula:	C ₂₈ H ₂₄ N ₂ O ₃		
Molecular Weight:	436.5		
Target:	MAGL		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (114.55 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.2910 mL	11.4548 mL	22.9095 mL
	5 mM	0.4582 mL	2.2910 mL	4.5819 mL
	10 mM	0.2291 mL	1.1455 mL	2.2910 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective ABHD6 inhibitor with an IC₅₀ of 430 nM^[1] [2]. WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylentetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice^[3].

REFERENCES

[1]. Daniel A Bachovchin, et al. Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):20941-6.

[2]. Peng Zhong, et al. Genetic deletion of monoacylglycerol lipase alters endocannabinoid-mediated retrograde synaptic depression in the cerebellum. J Physiol. 2011 Oct 15;589(Pt 20):4847-55.

[3]. Alipi V Naydenov, et al. ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice. Neuron. 2014 Jul 16;83(2):361-371.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA